ClinicalTrials.Veeva

Menu
F

Fundacion Respirar | Clinical Independency Research

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

BMS-986278
Anastrozole
AP01
Exemestane
Tamoxifen
Gedatolisib
Bemarituzumab
BIIB059
Litifilimab
Letrozole

Parent organization

This site is a part of Fundacion Respirar

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 10 total trials
Locations recently updated

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE)....

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: Litifilimab
Drug: Placebo

A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus pla...

Enrolling
Progressive Pulmonary Fibrosis
Drug: AP01
Other: Placebo
Locations recently updated

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive,...

Enrolling
Breast Cancer
Drug: Elacestrant
Drug: Tamoxifen

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

Enrolling
Moderate to Severe Asthma
Drug: ICS-LABA
Other: placebo

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: BMS-986278
Drug: BMS-986278 Placebo

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Enrolling
Progressive Pulmonary Fibrosis
Drug: BMS-986278 Placebo
Drug: BMS-986278

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...

Active, not recruiting
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Other: Placebo
Drug: Nivolumab

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant and CDK4/6 Inhibitors fo...

Enrolling
Breast Cancer
Drug: Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant
Drug: Arm B: Palbociclib or Ribociclib + Fulvestrant

The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS).

Enrolling
Small Cell Lung Cancer
Limited Stage Small Cell Lung Cancer
Drug: Placebo
Drug: Tarlatamab

Trial sponsors

Amgen logo
Bristol-Myers Squibb (BMS) logo
A
Biogen logo
C
Incyte logo
Lilly logo
Stemline Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems